Phenotypic analysis of CTCs from patients diagnosed with estrogen receptor (ER)-positive/HER2-negative breast cancer (through histological assessment of the primary tumor), highlighted that CTCs are capable of acquiring HER2 expression in the metastatic setting [39]. This evidence concerns the gene ESR1 and breast cancer.